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DESCRIPTION
Several cutaneous manifestations have been seen 
to be associated with SARS- CoV-2 infection since 
the beginning of the pandemic.1–3 Acute haemor-
rhagic oedema of infancy (AHEI) is a vasculitis that 
is expressed in the first 2 years of life; it is char-
acterised by purpuric lesions in the face, arms and 
legs, and is associated with oedema of the extrem-
ities. The intensity of the lesions contrasts with the 
benign course and good prognosis of this disease.4 5
A 14- month- old boy with a previous history of 
vesicoureteral reflux and recurrent pyelonephritis 
presented to the emergency department with a 
2- day history of fever and vomiting. Lab work 
showed leucocytosis (21.95 × 109/L), neutrophilia 
(11.55 × 109/L), mild thrombocytopenia (172 × 
109/L), elevated C reactive protein (221.8 mg/L) 
and normal procalcitonin (0.14 ng/mL). Urine test 
showed leucocyturia (237 U/L) but nitrites were 
negative. Therapy with cefuroxime and gentamycin 
was started intravenously. Although with no epide-
miology or respiratory symptoms, SARS- CoV-2 was 
detected by reverse transcription PCR (RT- PCR) in 
nasopharyngeal secretions during the preadmission 
screening. Urine and blood cultures were negative, 
and chest X- ray and renal ultrasound were normal. 
Favourable evolution was observed, and the infant 
was discharged 7 days later under cefuroxime anti-
biotic therapy.
The next day, palpable maculopapular and 
purpuric lesions with perilesional erythema were 
observed, beginning in the face with progressive 
extension to ears, abdomen, chest (figure 1), limbs, 
hands, and feet; this was followed by oedema of 
the extremities (figure 2). Large bruise- like lesions 
in the arms and limbs and small purpuric lesions 
in the face were not blanchable regarding vitro-
pression. The lesions were neither painful nor 
pruritic. No other symptoms were reported. Lab 
work showed leucocytes 13.34 × 109/L, elevated 
C reactive protein 80 mg/L, sedimentation rate 
74 mm/hour and D- dimers 846 ug/L. RT- PCR for 
PCR SARS- CoV-2 remained positive. All other 
respiratory viruses tested by PCR were negative. 
Regression of rash and oedema was observed in 
3 days with full recovery after 2 weeks, only with 
an antihistaminic. Exclusion of allergic reaction to 
cefuroxime was confirmed by an oral provocation 
test, performed with standardised doses adjusted to 
the child’s weight; this test was negative.
Because of the age, purpuric characteristics, 
swelling, localisation of the lesions (extremities, 
face and ears) and benign course without intern 
organ involvement, AHEI was the most probable 
diagnosis. Also, the association with prior viral 
infections has already been stated.5
Nevertheless, a differential diagnosis of Sweet 
syndrome (characterised by fever, neutrophilia and 
red plaques) should be considered. However, as this 
syndrome, usually rare in children, presents with 
Figure 1 Palpable purpuric and maculopapular lesions 
with perilesional erythema in acute haemorrhagic 
oedema of infancy (AHEI) in an infant with SARS- CoV-2 
infection.
Figure 2 Palpable purpuric and maculopapular lesions 
and oedema of the extremities in acute haemorrhagic 
oedema of infancy (AHEI) in an infant with SARS- CoV-2 
infection.
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painful tender plaques, papules and pustules, frequently asso-
ciated with inflammatory disorders and malignancies,6 we ruled 
out this diagnose. Finally, although there were some similarities 
with urticarial vasculitis,7 the fact that the lesions were non- 
pruritic, and there were no circumscribed weals with a white 
centre and only residual transient hyperpigmentation, we ruled 
out this last diagnosis and assumed AHEI vasculitis.
This case describes the association of AHEI to SARS- CoV-2 
infection as an atypical presentation of COVID-19. Therefore, 
this aetiology must be considered during the differential diag-
nosis of purpuric exanthema.
Learning points
 ► Cutaneous lesions are an atypical manifestation of COVID-19 
in children.
 ► SARS- CoV-2 infection must be considered in the differential 
diagnosis of purpuric exanthema, such as acute haemorrhagic 
oedema of infancy.
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